SB-269970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies. It was previously believed to act as a selective 5-HT7 receptor antagonist (or possibly inverse agonist) but a subsequent discovery showed that it also potently blocks the α2-adrenergic receptor.
This page contains content from the copyrighted Wikipedia article "SB-269970"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
